The Apex Times
Above the Noise
Business Wire
BusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex Times
Back to front
Pfizer licenses Chai Discovery’s AI model for antibody and biologics drug discovery
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 7, 8:28 PM EDT

Pfizer licenses Chai Discovery’s AI model for antibody and biologics drug discovery

The deal gives Pfizer early access to Chai-3 and a custom version of the platform built with Pfizer’s proprietary data, as the two companies move from AI research toward deployment inside drug discovery workflows.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Pfizer (NYSE: PFE) has signed a licensing agreement with Chai Discovery to use the company’s generative AI software in drug discovery, Chai Discovery announced this week. Under the arrangement, Pfizer will integrate Chai Discovery’s AI platform into its discovery operations and gain early access to Chai-3, the latest model in Chai’s antibody and biologics design stack.

The partnership is aimed at speeding up early-stage discovery, where traditional efforts often rely on lengthy experimental cycles and uncertain outcomes. Chai Discovery says its models can predict and redesign molecular interactions, helping scientists design biomolecules with targeted functional properties and compress the “discovery loops” that typically take months or years into shorter sprints.

Chai Discovery described Chai-3 as a step-change upgrade for AI-driven antibody design. It said the new model doubles the success rate of Chai’s predecessor and is designed to produce antibodies that meet therapeutic development requirements. The company also said Chai-3 improves capabilities tied to therapeutic binding, multi-specific antibody design, and the identification of molecules that bind hard-to-drug targets.

Chai Discovery added that the Pfizer integration will include a customized model built using Pfizer’s proprietary data and tailored to Pfizer’s workflows. The announcement positions the custom component as a way to adapt a frontier model to the specific decisions and data structures used by a large biopharmaceutical research organization.

The update builds on Chai Discovery’s earlier release, Chai-2, which Chai described as its first “zero-shot” antibody design platform. In that framing, zero-shot means the model can propose designs without needing task-specific training on prior examples, and Chai said Chai-2 achieved double-digit experimental hit rates and a large improvement in drug-like properties compared with previous computational approaches.

Pfizer has increasingly discussed the role of artificial intelligence across drug development, including how machine learning and natural language processing can help manage large volumes of data and automate parts of scientific and regulatory work. In a separate company article on AI, Pfizer described AI as a tool that can help speed clinical development tasks while human experts train and monitor systems to validate results.

Still, key deal specifics were not disclosed in the announcements reviewed here. Chai Discovery did not provide financial terms for the licensing agreement, and it did not name which specific therapeutic areas, targets, or early-stage programs Pfizer will prioritize first using Chai-3.

For Pfizer, the watch items are likely to be operational rather than financial in the near term: whether the Chai-3 deployment is used broadly across biologics discovery, and whether Pfizer subsequently reports more concrete outcomes, such as measurable changes in early candidate hit rates, reduction in design-to-experiment timelines, or progression of antibody programs enabled by the AI platform.

Why It Matters

  • The licensing suggests more large pharmaceutical companies are moving beyond AI experiments toward integrating “frontier” generative models into day-to-day discovery workflows.
  • Early access to an upgraded antibody model like Chai-3 reflects competitive pressure in biologics discovery, where improvements in hit rates and iteration speed can affect how quickly candidates advance.
  • A custom model tailored to a big pharma’s proprietary data indicates a shift from one-size-fits-all AI tools toward enterprise implementations that fit internal processes and datasets.
  • If Pfizer can translate the promised reduction in discovery timelines into measurable outcomes, it could influence how other companies evaluate and purchase AI drug discovery platforms.

Sources

Key Facts

  • Pfizer signed a licensing agreement with Chai Discovery to incorporate Chai’s AI platform into its drug discovery operations.
  • The deal provides Pfizer early access to Chai-3, Chai Discovery’s latest AI model for antibody and biologics design.
  • Chai Discovery said Chai-3 doubles the success rate of Chai-3’s predecessor in antibody design and is intended to generate therapeutic-standard antibodies.
  • The license includes access to a customized model built using Pfizer’s proprietary data and designed to fit Pfizer’s research workflows.
  • Chai Discovery said its approach can shorten early discovery cycles from months or years to much shorter sprints, including completion in weeks for some prior workflows.
  • The announcements reviewed did not disclose the financial terms of the licensing agreement or Pfizer’s specific target and therapeutic area focus under the deal.

Healthcare Related

Pfizer licenses Chai Discovery’s AI model for antibody and biologics drug discovery | The Apex Times